Nowotwory最新文献_第9页

The Nowotwory journal over the last 95 years (1923–2018) 《Nowotwory》杂志过去95年(1923-2018)

Nowotwory Pub Date : 2018-05-23 DOI: 10.5603/NJO.2017.0054

E. Towpik, W. Wysocki

{"title":"The Nowotwory journal over the last 95 years (1923–2018)","authors":"E. Towpik, W. Wysocki","doi":"10.5603/NJO.2017.0054","DOIUrl":"https://doi.org/10.5603/NJO.2017.0054","url":null,"abstract":"Launching of the journal and its development One of the first global initiatives for publishing a periodical devoted to the fight against cancer arose in Poland back in 1906, when both Dr Mikołaj Rejchmann and Dr Józef Jaworski from Warsaw set up an Anti-Cancer Committee (Komitet do Walki z Rakiem). One of its aims was to launch a journal, however this proved impossible due to the unfavourable conditions prevailing at that time. When Poland regained its independence, organising anti-cancer policies again became a priority. In July 1921, an Polish Anti-Cancer Committee (Polski Komitet do Zwalczania Raka) in Warsaw came into being. Despite scant resources it rapidly and enthusiastically started its operations. This was reflected by publishing a journal entitled The Bulletin of the Polish Anti-Cancer Committee (Biuletyn Polskiego Komitetu do Zwalczania Raka). The first edition was published in 1923, whose editor was Dr Stefan Sterling-Okuniewski, MD. At that time, this really was a pioneering endeavour as there were only 5 other such journals dedicated solely to the anti-cancer campaign in the world: the German Zeitschrift für Krebsforschung (1903), the Japanese Gann (1907), the French Bulletin de l’Association Francaise pour l’Etude du Cancer (1909), the Italian Tumori (1911) and from the USA Journal of Cancer Research (1916)1. As a comparison, the","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"7 1","pages":"321-335"},"PeriodicalIF":0.0,"publicationDate":"2018-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85647035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should adjuvant therapy be used in patients with colorectal cancer in pathological stage II 病理II期结直肠癌患者是否需要辅助治疗

Nowotwory Pub Date : 2018-05-23 DOI: 10.5603/NJO.2017.0062

R. Stec

引用次数: 0

Malakoplakia in a colonic tubular adenoma: a unique case presentation 结肠管状腺瘤的斑疹:一个独特的病例表现

Nowotwory Pub Date : 2018-05-23 DOI: 10.5603/NJO.2017.0059

Akash Gupta, Abdalla Saad Abdalla Al-Zawi, A. Naqvi, S. Salama, Emraga Abohamod, S. Alowami

引用次数: 0

Should patients with stage II colon cancer be treated with adjuvant chemotherapy II期结肠癌患者是否应该接受辅助化疗

Nowotwory Pub Date : 2018-05-23 DOI: 10.5603/NJO.2017.0063

A. Deptała

{"title":"Should patients with stage II colon cancer be treated with adjuvant chemotherapy","authors":"A. Deptała","doi":"10.5603/NJO.2017.0063","DOIUrl":"https://doi.org/10.5603/NJO.2017.0063","url":null,"abstract":"Patients with stage II colon cancer, as defined by pTNM/AJCC 2017, when analysed with regards to the risk of recurrence and to DFS and OS prolongation with adjuvant chemotherapy, make up a heterogenous patient population. That is why, a qualified oncologist, who makes a decision to apply adjuvant chemotherapy, taking into consideration the patient’s well-being, should formulate a post-operative strategy, the main objective of which will be to minimise the risk of cancer recurrence and to prolong survival. The author of this paper believes that adjuvant chemotherapy should be provided for every patient in the very high risk group (IIC) and high risk group (IIA/IIB MSI-L/MSS and inadequate lymphadenectomy and BRAF mutation), and also in the group of intermediate risk of cancer recurrence (IIA/IIB MSI-L/MSS with an adequate scope of lymphadenectomy and BRAF mutation as well as IIA MSI-L/MSS with inadequate scope of lymphadenectomy and lack of BRAF mutation), after obtaining the patient’s informed consent. In a situation when an oncologist is unable to obtain the result of microsatellite instability or the BRAF gene mutation, it would be advisable to refer the patient to a centre which has access to such tests; this would allow the adjuvant chemotherapy to have optimum application, which would by all means translate into the improvement of the treatment results in patients with colon cancer.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"45 1","pages":"380-384"},"PeriodicalIF":0.0,"publicationDate":"2018-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75749994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is telepathology worth being developed 心灵病理学值得发展吗

Nowotwory Pub Date : 2018-05-23 DOI: 10.5603/NJO.2017.0061

W. Olszewski

{"title":"Is telepathology worth being developed","authors":"W. Olszewski","doi":"10.5603/NJO.2017.0061","DOIUrl":"https://doi.org/10.5603/NJO.2017.0061","url":null,"abstract":"In pathology, similarly to other branches of medicine, and in particular in the field of visualisation techniques, the use of image transmission via the Internet for diagnostic or consulting purposes is being introduced. One of the reasons for this is the limited number of specialists. Currently, three basic applications of this technique can be distinguished: telediagnostics, teleconsultations and teleconferences. In contrast to teleradiology where the basic subject of analysis is the image obtained by various visualisation techniques — in pathology, the basis is tissue or cell analysis. The evaluation of such material should be from the start in the hands of pathomorphologists. The transmitted image of the performed histological preparation may not be fully representative of the lesion being examined (cancer). In modern oncological pathomorphology, it is very often necessary to use special techniques such as immunohistology or molecular biology techniques to determine the proper diagnosis. Performing such tests requires direct access to tissue or cytological material. Telepathology can be used as part of consultations between reference centres. Modern telepathology techniques allow the use of these methods for training purposes, including the interactive participation of trainees.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"28 1","pages":"372-374"},"PeriodicalIF":0.0,"publicationDate":"2018-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78000673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is AIO belly board device advantageous in all rectal cancer patients AIO腹板装置是否适用于所有直肠癌患者

Nowotwory Pub Date : 2018-05-23 DOI: 10.5603/NJO.2017.0056

D. Hempel, Joanna Mandrosz, M. Wojtukiewicz, T. Filipowski, E. Sierko

引用次数: 0

Bone marrow sparing RT in era of immunotherapy 免疫治疗时代的骨髓保留RT

Nowotwory Pub Date : 2018-02-22 DOI: 10.5603/NJO.2017.0050

Ł. Kuncman, Malwina Pietrzykowska-Kuncman, J. Danielska, Jolanta Łuniewska-Bury, J. Fijuth

引用次数: 1

Current possibilities of peri-operative evaluation of the radicality of primary tumour resection in breast cancer patients treated with BCT (breast conserving treatment) BCT(保乳治疗)乳腺癌原发肿瘤切除根治性围手术期评价的现状

Nowotwory Pub Date : 2018-02-22 DOI: 10.5603/NJO.2017.0047

T. Nowikiewicz, W. Zegarski